Stay updated on Anlotinib in Advanced Gastrointestinal Stromal Tumor Clinical Trial

Sign up to get notified when there's something new on the Anlotinib in Advanced Gastrointestinal Stromal Tumor Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Anlotinib in Advanced Gastrointestinal Stromal Tumor Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The study page displays details for a Phase 2 trial of anlotinib for advanced gastrointestinal stromal tumors after imatinib failure, including its eligibility criteria, progression-free-survival outcome, and recruiting site in Beijing, China.
    Difference
    41%
    Check dated 2026-11-07T12:40:08.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The site footer’s revision label changed from v3.7.2 to v3.8.0; the study record remains inaccessible behind a 403 error.
    Difference
    0.2%
    Check dated 2026-10-31T13:30:29.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    A banner announces NIH website updates and says federal agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T13:05:13.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.1 to v3.7.2; the page otherwise remains a 403 Forbidden error page.
    Difference
    0.2%
    Check dated 2026-10-17T13:25:09.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier changed from v3.7.0 to v3.7.1, while the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T14:06:32.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with a minimal header and a Home link, replacing the study content and indicating that access to the record is blocked.
    Difference
    17%
    Check dated 2026-09-19T19:12:17.000Z thumbnail image

Stay in the know with updates to Anlotinib in Advanced Gastrointestinal Stromal Tumor Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Anlotinib in Advanced Gastrointestinal Stromal Tumor Clinical Trial page.